Louis Elan D, Bennett David A
G.H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Mov Disord. 2007 Sep 15;22(12):1681-8. doi: 10.1002/mds.21433.
Mild Parkinsonian signs (MPS) include gait and balance changes, rigidity, bradykinesia, and tremor. MPS can occur commonly during the clinical examination of older people who do not have known neurological disease, with prevalence estimates for MPS as a whole ranging from 15% to 95%. MPS are generally progressive and they are coupled with functional difficulties, impaired gait and balance, and increased risks of mild cognitive impairment, dementia, and mortality. The mechanistic basis for these signs is unclear, but is likely to be multifactorial, with possible factors including an age-associated decline in dopaminergic nigrostriatal activity, the early development of neurodegenerative (Lewy body or Alzheimer's type) pathologies in the basal ganglia, or the accumulation of vascular pathology in the brain. It would be valuable to identify those individuals with MPS who are at increased risk for the development of future Alzheimer's disease, full-blown Parkinson's disease, or strokes, and to develop therapeutic strategies to intervene to lessen the likelihood of MPS-related morbidity and mortality.
轻度帕金森氏体征(MPS)包括步态和平衡改变、僵硬、运动迟缓及震颤。在无已知神经疾病的老年人临床检查中,MPS较为常见,MPS总体患病率估计在15%至95%之间。MPS通常呈进行性发展,且与功能障碍、步态和平衡受损以及轻度认知障碍、痴呆和死亡风险增加相关。这些体征的机制基础尚不清楚,但可能是多因素的,可能因素包括多巴胺能黑质纹状体活动随年龄下降、基底节区神经退行性(路易体或阿尔茨海默病类型)病变的早期发展,或脑部血管病变的累积。识别那些患未来阿尔茨海默病、全面帕金森病或中风风险增加的MPS个体,并制定治疗策略进行干预,以降低与MPS相关的发病率和死亡率,将具有重要意义。